{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:04:14Z","timestamp":1774343054090,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,25]]},"DOI":"10.7759\/cureus.16619","type":"journal-article","created":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T20:30:55Z","timestamp":1627245055000},"source":"Crossref","is-referenced-by-count":5,"title":["Thrombotic Thrombocytopenic Purpura Presentation in an Elderly Gentleman Following COVID Vaccine Circumstances"],"prefix":"10.7759","author":[{"given":"Karthik","family":"Chamarti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khavar","family":"Dar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anika","family":"Gundlapalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Mourning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelash","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Acquired TTP: Clinical manifestations and diagnosis","author":"George JN","year":"2019","unstructured":"George JN, Cuker A. Acquired TTP: Clinical manifestations and diagnosis. Leung LK, Tirnauer JS (ed): Waltham, MA; 2019."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features","volume":"60","author":"Reese JA","year":"2013","unstructured":"Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer. 2013, 60:1676-1682. 10.1002\/pbc.24612","journal-title":"Pediatr Blood Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13764","article-title":"Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics","volume":"15","author":"Saha M","year":"2017","unstructured":"Saha M, McDaniel JK, Zheng XL. Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics. J Thromb Haemost. 2017, 15:1889-1900. 10.1111\/jth.13764","journal-title":"J Thromb Haemost"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197712222972507","article-title":"Treatment of thrombotic thrombocytopenic purpura with plasma","volume":"297","author":"Byrnes JJ","year":"1977","unstructured":"Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med. 1977, 297:1386-1389. 10.1056\/NEJM197712222972507","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock GA","year":"1991","unstructured":"Rock GA, Shumak KH, Buskard NA, et al.. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991, 325:393-397. 10.1056\/NEJM199108083250604","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010","volume":"116","author":"George JN","year":"2010","unstructured":"George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010, 116:4060-4069. 10.1182\/blood-2010-07-271445","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-2-200301210-00011","article-title":"Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab","volume":"138","author":"Zheng X","year":"2003","unstructured":"Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med. 2003, 138:105-108. 10.7326\/0003-4819-138-2-200301210-00011","journal-title":"Ann Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.02082.x","article-title":"Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura","volume":"49","author":"Swisher KK","year":"2009","unstructured":"Swisher KK, Terrell DR, Vesely SK, Kremer Hovinga JA, L\u00e4mmle B, George JN. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion. 2009, 49:873-887. 10.1111\/j.1537-2995.2008.02082.x","journal-title":"Transfusion"},{"key":"ref9","unstructured":"Pfizer-BioNTech COVID-19 Vaccine Overview and Safety. (2021). Accessed. May 20, 2021: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines\/Pfizer-BioNTech.html."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26132","article-title":"Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination","volume":"96","author":"Lee EJ","year":"2021","unstructured":"Lee EJ, Cines DB, Gernsheimer T, et al.. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021, 96:534-537. 10.1002\/ajh.26132","journal-title":"Am J Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpa.2007.04.013","article-title":"From tolerance to autoimmunity: is there a risk in early life vaccination?","volume":"137","author":"Goriely S","year":"2007","unstructured":"Goriely S, Goldman M. From tolerance to autoimmunity: is there a risk in early life vaccination?. J Comp Pathol. 2007, 137:S57-S61. 10.1016\/j.jcpa.2007.04.013","journal-title":"J Comp Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00342","article-title":"Pattern recognition and signaling mechanisms of RIG-I and MDA5","volume":"5","author":"Reikine S","year":"2014","unstructured":"Reikine S, Nguyen JB, Modis Y. Pattern recognition and signaling mechanisms of RIG-I and MDA5. Front Immunol. 2014, 5:342. 10.3389\/fimmu.2014.00342","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v8.i17.3621","article-title":"Autoimmunity as the comet tail of COVID-19 pandemic","volume":"8","author":"Talotta R","year":"2020","unstructured":"Talotta R, Robertson E. Autoimmunity as the comet tail of COVID-19 pandemic. World J Clin Cases. 2020, 8:3621-3644. 10.12998\/wjcc.v8.i17.3621","journal-title":"World J Clin Cases"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/62751-thrombotic-thrombocytopenic-purpura-presentation-in-an-elderly-gentleman-following-covid-vaccine-circumstances","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:27:39Z","timestamp":1707506859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/62751-thrombotic-thrombocytopenic-purpura-presentation-in-an-elderly-gentleman-following-covid-vaccine-circumstances"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,25]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.16619","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,25]]}}}